Solvias Launches a State-of-the-Art Center for Biologics
Solvias, a premier global provider of chemistry, manufacturing, and control (CMC) analytics, is thrilled to announce the launch of its new Center of Excellence for Biologics and Cell and Gene Therapy. This facility, located in the dynamic area of Research Triangle Park, is set to be a beacon of innovation and excellence in the life sciences field.
Facility Overview and Features
Spanning an impressive 50,000 square feet, Solvias' new center is designed to support large molecule analytical services. This flagship North American site aims to significantly accelerate the development and commercialization of groundbreaking biologics. The center plans to create approximately 200 new jobs within the research and innovation landscape over the course of three years.
Phased Rollout for Enhanced Capabilities
The establishment of this center unfolds in two distinct phases. Phase 1 includes a 20,000-square-foot space dedicated to cGMP release testing, featuring advanced cell-based potency and molecular assays. This initial phase is already operational, setting the stage for cutting-edge testing services.
Looking ahead, Phase 2 will add another 30,000 square feet, focusing on advanced stability testing and biophysical characterization, with an expected opening by mid-2025. This phased approach allows for immediate service availability while reinforcing the facility's capabilities.
Advanced Technologies for Greater Impact
The new center boasts state-of-the-art analytical instruments, laboratory automation, and sophisticated digital management systems, all tailored for comprehensive GMP testing. Solvias aims to support a variety of biologics, including cell and gene therapies, monoclonal antibodies (mAbs), and beyond, addressing needs from preclinical stages through to commercial release.
Leadership Insights and Vision
In a recent statement, Archie Cullen, the Chief Executive Officer of Solvias, highlighted the significance of this new center in the company’s growth journey. He emphasized the integration of their team’s expertise with cutting-edge technology, aiming to create reliable, high-quality analytical support for clients. This commitment, he noted, will help in bringing transformative therapies to patients around the globe.
Further, Ilya Koltover, Chief Commercial Officer of Solvias, expressed a strong focus on talent acquisition to enhance their technical partnerships. By fostering collaborations with clients, Solvias intends to expedite therapies to market, remaining firmly integrated within the U.S. biopharma ecosystem.
Expanding Global Reach
The inauguration of this center signifies an important expansion in Solvias' global footprint, marking it as their second site in North America and adding to their robust portfolio of six centers of excellence worldwide. This growth aligns with Solvias' mission to offer comprehensive, innovative solutions across the life sciences sector.
For further information about Solvias’ new initiatives and capabilities in RTP, please visit solvias.com.
About Solvias
Solvias is renowned for its expertise in providing chemistry, manufacturing, and control analytics to the life sciences industry. With a blend of extensive experience and regulatory knowledge, Solvias is dedicated to offering comprehensive solutions that range from raw material testing to the release of drug products and API development, particularly in small molecules.
Headquartered near Basel, Switzerland, the company operates its centers while adhering to the highest international standards—ISO, GMP, GLP, and FDA compliance, ensuring that they remain at the forefront of biopharmaceutical innovations and analytics.
Frequently Asked Questions
What is the purpose of Solvias’ new Center of Excellence?
The Center is designed to enhance large molecule analytical services, supporting the development and commercialization of innovative biologics.
How many new jobs will the new center create?
The center is projected to create approximately 200 new jobs in the research and innovation field over the next three years.
What are the two phases of the center’s rollout?
Phase 1 involves 20,000 square feet for cGMP release testing, while Phase 2 will add 30,000 square feet for stability testing and biophysical characterization.
What types of therapies will the new center support?
The center will support cell and gene therapies, monoclonal antibodies, and other biologics from preclinical to commercial stages.
How does Solvias ensure compliance with global standards?
Solvias adheres to the highest standards, including ISO, GMP, GLP, and FDA regulations, to maintain quality and safety across its services.
